Clinical Trial

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Study acronym: XCGD-MOBI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2017-02-13; most recent amendment 2025-09-12.
Trial Details
NCT Number NCT03055247
Lead Sponsor IRCCS San Raffaele
Collaborators: Fondazione Telethon
Conditions Chronic Granulomatous Disease X-linked (X-CGD)
Enrollment 3 participants
Start Date 2015-11-06
Primary Completion 2023-07-13 (estimated)
Study Completion 2026-07-18 (estimated)
Updated on ClinicalTrials.gov 2025-09-18